IP Library Granted Patent US 11,987,619
Granted Patent B2
US 11,987,619 · App. 17/870,373 · Granted May 21, 2024

Single-chain chimeric polypeptides and uses thereof

Inventor: Hing Wong (Miramar, FL)
Assignee: HCW Biologics, Inc.
C07K16/18A61P3/10C07K16/2809C07K16/2818C07K16/2866C12N5/0637A61K39/00C07K2317/24C07K2317/56C07K2317/622C07K2319/00C12N2501/998
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,987,619
App. No.
17/870,373
Granted
May 21, 2024
Kind
B2
Abstract

Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.

Claims (42)

1. A nucleic acid encoding a single-chain chimeric polypeptide comprising:

(i) a first target-binding domain comprising a sequence at least 80% identical to SEQ ID NO: 28;

(ii) a soluble tissue factor domain that does not have coagulation activity, wherein the soluble tissue factor domain comprises a sequence at least 80% identical to SEQ ID NO: 9; and

(iii) a second target-binding domain comprising a sequence at least 80% identical to SEQ ID NO: 28,

wherein the single-chain chimeric polypeptide does not stimulate blood coagulation in a mammal.

2. The nucleic acid of claim 1 , wherein the first target-binding domain and the soluble tissue factor domain directly abut each other.

3. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide further comprises a linker sequence between the first target-binding domain and the soluble tissue factor domain.

4. The nucleic acid of claim 1 , wherein soluble tissue factor domain and the second target-binding domain directly abut each other.

5. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide further comprises a linker sequence between the soluble tissue factor domain and the second target-binding domain.

6. The nucleic acid of claim 1 , wherein the soluble tissue factor domain is a soluble human tissue factor domain that does not have coagulation activity.

7. The nucleic acid of claim 1 , wherein the soluble tissue factor domain comprises or consists of a sequence from a wildtype soluble human tissue factor.

8. The nucleic acid of claim 1 , wherein the first target-binding domain and the second target-binding domain are human IL-2.

9. A vector comprising the nucleic acid of claim 1 .

10. A cell comprising the nucleic acid of claim 1 .

11. A method of producing a single-chain chimeric polypeptide, the method comprising:

culturing the cell of claim 10 in a culture medium under conditions sufficient to result in the production of the single-chain chimeric polypeptide; and

recovering the single-chain chimeric polypeptide from the cell and/or the culture medium.

12. The nucleic acid of claim 1 , wherein:

the first target-binding domain comprises a sequence at least 90% identical to SEQ ID NO: 28;

the soluble tissue factor domain comprises a sequence at least 90% identical to SEQ ID NO: 9; and

the second target-binding domain comprises a sequence at least 90% identical to SEQ ID NO: 28.

13. The nucleic acid of claim 1 , wherein:

the first target-binding domain comprises a sequence at least 95% identical to SEQ ID NO: 28;

the soluble tissue factor domain comprises a sequence at least 95% identical to SEQ ID NO: 9; and

the second target-binding domain comprises a sequence at least 95% identical to SEQ ID NO: 28.

14. The nucleic acid of claim 1 , wherein:

the first target-binding domain comprises SEQ ID NO: 28;

the soluble tissue factor domain comprises SEQ ID NO: 9; and

the second target-binding domain comprises SEQ ID NO: 28.

15. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 108.

16. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 108.

17. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide comprises a sequence that is at least 95% identical to SEQ ID NO: 108.

18. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide comprises SEQ ID NO: 108.

19. The nucleic acid of claim 18 , wherein the nucleic acid comprises the sequence of SEQ ID NO: 109.

20. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 110.

21. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 110.

22. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide comprises a sequence that is at least 95% identical to SEQ ID NO: 110.

23. The nucleic acid of claim 1 , wherein the single-chain chimeric polypeptide comprises SEQ ID NO: 110.

24. The nucleic acid of claim 22 , wherein the nucleic acid comprises the sequence of SEQ ID NO: 111.

25. A composition comprising the nucleic acid of claim 1 .

26. A kit comprising the nucleic acid of claim 1 .

27. The vector of claim 9 , wherein the vector is an expression vector.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: HCW BIOLOGICS INC.
To: IMMUNITYBIO, INC.
Reel/Frame 068014/0474 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2022
From: WONG, HING
To: HCW BIOLOGICS, INC.
Reel/Frame 060641/0467 →
Continuity (9)
Division 16556040 · Aug 29, 2019
Provisional Application 62881039 · Jul 31, 2019
Provisional Application 62817241 · Mar 12, 2019
Provisional Application 62817244 · Mar 12, 2019
Provisional Application 62816683 · Mar 11, 2019
Provisional Application 62749506 · Oct 23, 2018
Provisional Application 62746832 · Oct 17, 2018
Provisional Application 62725038 · Aug 30, 2018
Related Publication 20230039157A1 · Feb 9, 2023